British chemist and entrepreneur David Spivack faces severe US prison exposure over alleged importation of a banned LSD-related hallucinogen developed through legal analog research

British chemist and entrepreneur David Spivack is linked to legal LSD-based hallucinogen research and faces US criminal accusations over allegedly importing a banned psychedelic compound. The case centers on the gap between substances designed as legal analogs and drug laws that can rapidly reclassify them as controlled imports. US enforcement risk appears central, with the prospect of harsh sentencing presented as a major consequence for cross-border trade in novel psychoactive substances. The underlying issue reaches beyond one person and highlights how psychedelic gray-market chemistry, commercial innovation, and prohibition collide when LSD-related compounds move from legal experimentation into customs, criminal law, and public safety scrutiny.